Reduction in sudden death and total mortality by antiarrhythmic therapy evaluated by electrophysiologic drug testing: criteria of efficacy in patients with sustained ventricular tachyarrhythmia

Reports of the results of electrophysiologic testing of antiarrhythmic regimens have concentrated on inducibility of ventricular tachycardias during drug treatment. Many drug regimens, however, affect the tachycardia but fail to prevent its initiation. In this study, 258 patients who underwent serial electrophysiologic studies were followed up. The patients were divided into three groups on the basis of the results of electrophysiologic testing. Group 1 included patients in whom the initiation of ventricular tachycardia was prevented by the drug regimen. In groups 2 and 3 the ventricular tachycardia was still inducible with the discharge drug regimen. In group 2, the drug regimen demonstrated a beneficial response (that is, the tachycardia cycle length increased by greater than 100 ms and the tachycardia did not produce severe symptoms). In group 3, the regimen did not produce a beneficial response. During follow-up, recurrence of sustained ventricular tachycardia occurred in 7 (7%) of 103 group 1 patients but in 20 (39%) of 51 and 52 (50%) of 104 group 2 and 3 patients, respectively. However, the total mortality and sudden death mortality rates were substantially reduced in group 2 (12 and 4%, respectively) compared with group 3 (39 and 34%). In fact, the total mortality and sudden death mortality in groups 1 and 2 were not significantly different. Thus, under certain circumstances, a drug regimen that produces a beneficial response may be an acceptable clinical alternative, particularly when no regimen prevents induction of ventricular tachycardia.

This article has been cited by other articles:

				American College of Cardiology Foundation, American Heart Association Task Force on Practice, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interve, Society for Vascular Medicine, Society for Vascular Surgery, L. A. Fleisher, et al. 2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery J. Am. Coll. Cardiol., November 24, 2009; 54(22): e13 - e118. [Full Text] [PDF]

				2007 WRITING COMMITTEE MEMBERS, L. A. Fleisher, J. A. Beckman, K. A. Brown, H. Calkins, E. L. Chaikof, K. E. Fleischmann, W. K. Freeman, J. B. Froehlich, E. K. Kasper, et al. 2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation, November 24, 2009; 120(21): e169 - e276. [Full Text] [PDF]

				L. A. Fleisher, J. A. Beckman, K. A. Brown, H. Calkins, E. L. Chaikof, K. E. Fleischmann, W. K. Freeman, J. B. Froehlich, E. K. Kasper, J. R. Kersten, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery J. Am. Coll. Cardiol., October 23, 2007; 50(17): e159 - e242. [Full Text] [PDF]

				L. A. Fleisher, J. A. Beckman, K. A. Brown, H. Calkins, E. L. Chaikof, K. E. Fleischmann, W. K. Freeman, J. B. Froehlich, E. K. Kasper, J. R. Kersten, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Circulation, October 23, 2007; 116(17): e418 - e500. [Full Text] [PDF]

				D. J. Callans Patients With Hemodynamically Tolerated Ventricular Tachycardia Require Implantable Cardioverter-Defibrillators Circulation, September 4, 2007; 116(10): 1196 - 1203. [Full Text] [PDF]

				J.u. Schlapfer, F. Rapp, L. Kappenberger, and M. Fromer Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: Results of long-term follow-up J. Am. Coll. Cardiol., June 5, 2002; 39(11): 1813 - 1819. [Abstract] [Full Text] [PDF]

				D. G. Wyse, M. Talajic, G. E. Hafley, A. E. Buxton, L. B. Mitchell, T. K. Kus, D. L. Packer, W. H. Kou, R. Lemery, P. Santucci, et al. Antiarrhythmic drug therapy in the Multicenter UnSustained Tachycardia Trial (MUSTT): drug testing and as-treated analysis J. Am. Coll. Cardiol., August 1, 2001; 38(2): 344 - 351. [Abstract] [Full Text] [PDF]

				M. E. Josephson, D. J. Callans, and A. E. Buxton The Role of the Implantable Cardioverter-Defibrillator for Prevention of Sudden Cardiac Death Ann Intern Med, December 5, 2000; 133(11): 901 - 910. [Abstract] [Full Text] [PDF]

				R. Ruppel, C. A. Schluter, S. Boczor, T. Meinertz, M. Schluter, K.-H. Kuck, and R. Cappato Ventricular tachycardia during follow-up in patients resuscitated from ventricular fibrillation: experience from stored electrograms of implantable cardioverter-defibrillators J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1724 - 1730. [Abstract] [Full Text] [PDF]

				M. K. Chung, S. M. Pogwizd, D. P. Miller, and M. E. Cain Three-dimensional Mapping of the Initiation of Nonsustained Ventricular Tachycardia in the Human Heart Circulation, June 3, 1997; 95(11): 2517 - 2527. [Abstract] [Full Text]

				N. Nasir Jr., U. S. Swarna, K. A. Boahene, T. K. Doyle, and A. Pacifico Therapy of Sustained Ventricular Arrhythmias With Amiodarone: Prediction of Efficacy With Serial Electrophysiologic Studies Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 1996; 1(2): 123 - 132. [Abstract] [PDF]

				E. F.D. Wever, R. N.W. Hauer, G. Schrijvers, F. J.L. van Capelle, J. G.P. Tijssen, H. J.G.M. Crijns, A. Algra, H. Ramanna, P. F.A. Bakker, and E. O. Robles de Medina Cost-effectiveness of Implantable Defibrillator as First-Choice Therapy Versus Electrophysiologically Guided, Tiered Strategy in Postinfarct Sudden Death Survivors : A Randomized Study Circulation, February 1, 1996; 93(3): 489 - 496. [Abstract] [Full Text]

				J. A. Reiffel Data-driven Decisions: The Importance of Clinical Trials in Arrhythmia Management Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1996; 1(1): 79 - 88. [Abstract] [PDF]

				R. Sheldon, H. Duff, and M. L. Koshman Antiarrhythmic Activity of Quinine in Humans Circulation, November 15, 1995; 92(10): 2944 - 2950. [Abstract] [Full Text]

				J. M. Herre, C. Titus, M. Oeff, M. Eldar, M. R. Franz, J. C. Griffin, and M. M. Scheinman Inefficacy and Proarrhythmic Effects of Flecainide and Encainide for Sustained Ventricular Tachycardia and Ventricular Fibrillation Ann Intern Med, November 1, 1990; 113(9): 671 - 676. [Abstract] [PDF]

				F. E. Marchlinski Treatment of Sustained Ventricular Arrhythmias: Which Therapy to Use? Ann Intern Med, October 1, 1988; 109(7): 522 - 525. [Abstract] [PDF]